Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey


Yozgat A. K. , LEBLEBİSATAN G. , AKBAYRAM S., Ozel S. C. , Karakas Z., ERDURAN E., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.3, pp.139-144, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.4274/tjh.galenos.2020.2019.0380
  • Title of Journal : TURKISH JOURNAL OF HEMATOLOGY
  • Page Numbers: pp.139-144

Abstract

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.